Skip to main content
. 2022 Jan 8;14(2):307. doi: 10.3390/cancers14020307

Figure 1.

Figure 1

Mechanism of action of anti PD-1/L1. Activated T cells express PD-1, and when it binds to PD-L1/2 on tumor cells, it results in T-cell depletion. Durvalumab, avelumab and atezolizumab block PD-L1, while pembrolizumab and nivolumab block PD-1 to produce antitumor responses.